Immuneoncia

Developer of monoclonal and specific antibody for cancer treatment

placeSeongnam-si, Gyeonggi-do, South Korea calendar_todayFounded 2016 groups21 employees language immuneoncia.com

Registered entities

Social engagement

Social engagement: 563 social following, 1 post in the last 12 months — top 10% of its industry.

Investor mix

9 investors on record; lead investors include Yuhan Corporation; 3 have since exited.

Investor typeCountShare
Venture capital333%
Private equity333%
Other / undisclosed333%
Coming soon